A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Building closer relationships with facility staff and health care partners of nursings homes, such as hospital providers and pharmacies, is going to be ...

The Centers for Medicare & Medicaid Services (CMS) issued a revised memo Wednesday to strengthen the Special Focus Facility (SFF) program, directing ...

A major study led by the University of Hertfordshire has shown how linking care home data with NHS and social care records can improve residents' lives, strengthen policy decision-making and ensure ...

Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...

Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International ...

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...

Adtalem Global Education changed its name to Covista last week, a move the company says signals its ambitions in addressing ...

The Centers for Medicare & Medicaid Services is changing how states select candidates for the Special Focus Facility Program ...

CMS appears to have made even more changes to its antipsychotic quality measure without advance notice, experts say. One consequence could be lower star ratings of which providers are unaware.

Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.